Pharmacological Nrf2 activator is therefore expected to ameliorate insulin resistance by counteracting obesity-induced oxidative stress and inflammation and maintaining oxidant and antioxidant homeostasis. The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.